Idle Cash, page-39

Ok so with Amgen it goes something like this:

We received the non refundable deposit of $15m, for us to use as we see fit. Then we received this:

"Under the strategic collaboration, Unilife can receive up to $75 million. At closing, Amgen paid a nonrefundable $20 million license fee and purchased a $30 million senior secured convertible note from Unilife. Amgen may purchase up to an additional $25 million in senior secured convertible notes over the next two years ($15 million in January 2017 and $10 million in January 2018). These payments are in addition to Amgen’s $15 million payment to Unilife in connection with the exclusivity letter entered into on December 31, 2015"

If you go back over the quarterlies you will see that the $15m was received (Dec qtr) and the $20m was also (march qtr), these fees are for access only so the company can use it for how they see fit really, though OrbiMed may still have some say there. Then it shows the $30m convertible note as proceeds from borrowings. This $30m is where Amgen may use this for customisation, development works and even discounts on future device purchases, not to mention the possibility of converting this into UNIS shares (though I doubt they will).